ClinicalTrials.gg
CompletedNCT00022698Updated Apr 15, 2016Results posted

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

A Phase 2 interventional study of Capecitabine and Irinotecan in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.

Enrollment
74th of 173
67 · median 55
Started
2001
with 2 others
Phase 2
100 of 179
16 open now
Registered
4th of 179
by date
Lead sponsor
16 of 179
Hoffmann-La Roche

Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 74th largest by enrollment of the 173 interventional ones that give a count, is one of 3 that started in 2001, is one of 100 in phase 2, and was the 4th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 24 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies testing capecitabine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.

Read the detailed description

OBJECTIVES:

Primary:

  • Determine the overall objective response rate in patients with locally advanced, locally recurrent, or metastatic colorectal cancer treated with capecitabine and irinotecan.

Secondary:

  • Determine the time to treatment failure, time to overall response, duration of overall response, duration of overall complete response, and time to progression in patients treated with this regimen.
  • Determine the 1-year survival and overall survival of patients treated with this regimen.
  • Determine the toxicity and safety profile of this regimen in these patients.
  • Determine the feasibility of predicting responses to this regimen by the molecular profile of tumor tissue in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive oral capecitabine twice daily on days 2-15 and irinotecan IV over 90 minutes on days 1 and 8. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients maintaining a response or stable disease after 12 courses may continue treatment at the discretion of the investigator.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study within 9 months.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • stage III colon cancer
  • stage IV colon cancer
  • stage III rectal cancer
  • stage IV rectal cancer
  • recurrent colon cancer
  • recurrent rectal cancer
  • adenocarcinoma of the colon
  • adenocarcinoma of the rectum
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed locally advanced, locally recurrent, or colorectal adenocarcinoma
  • At least 1

    • At least 10 mm by spiral CT scan
    • At least 20 mm by conventional techniques
    • Bone metastases, ascites, or pleural effusions are not considered measurable disease
  • No evidence of

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • 80-100%

:

  • Not specified

Hematopoietic:

  • at least 1,500/mm\^3
  • count at least 100,000/mm\^3

Hepatic:

  • no greater than 1.25 times (ULN)
  • and AST no greater than 2.5 times ULN (5 times ULN if liver metastases present)
  • Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN if liver metastases present or 10 times ULN if bone metastases present)
  • No known Gilbert's disease

Renal:

  • Creatinine no greater than 1.5 times ULN
  • at least 50 mL/min

Cardiovascular:

  • No cardiac disease
  • No congestive heart failure
  • No symptomatic coronary artery disease
  • No cardiac arrhythmias uncontrolled with medication
  • No myocardial infarction within the past 12 months

Gastrointestinal:

  • Able to swallow tablets
  • No lack of physical integrity of the upper gastrointestinal tract
  • No malabsorption syndrome

Other:

  • No prior unanticipated severe reaction to fluoropyrimidine therapy
  • No to fluorouracil
  • No history of uncontrolled seizures or CNS disorders
  • No psychological illness or condition that would preclude study entry
  • No other within the past 5 years except curatively treated basal cell skin cancer or carcinoma in situ of the cervix
  • No serious infection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 12 months since prior or adjuvant, active or passive immunotherapy
  • No concurrent active or passive immunotherapy (e.g., 17-1A antibody) for colon cancer
  • No concurrent prophylactic hematopoietic growth factors

Chemotherapy:

  • At least 12 months since prior neoadjuvant or adjuvant cytotoxic chemotherapy
  • No prior chemotherapy for metastatic colorectal cancer
  • No prior therapy with irinotecan or capecitabine
  • No other concurrent cytotoxic agents

Endocrine therapy:

  • Not specified

Radiotherapy:

  • At least 4 weeks since prior radiotherapy
  • No prior radiotherapy to measurable lesion (newly arising lesions in a previously irradiated area allowed)
  • No concurrent radiotherapy

Surgery:

  • At least 4 weeks since prior major surgery and recovered
  • No prior organ allograft

Other:

  • At least 4 weeks since prior participation in an drug study
  • No other concurrent investigational drugs
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Cohort 1,Initial Regimen:(Capecitabine + Irinotecan )

    Participants will receive capecitabine (Xeloda) 1000 mg/m\^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 125 mg/m\^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who are responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).

    Drug: Capecitabine · Drug: Irinotecan

  • Experimental
    Cohort 2,Amended Regimen:(Capecitabine + Irinotecan)

    Participants will receive capecitabine 900 mg/m\^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 100 mg/m\^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who will be responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).

    Drug: Capecitabine · Drug: Irinotecan

Interventions

06

What researchers measure

Primary outcomes

  1. Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0)

    Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as a greater than or equal to (\>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD. Participants who did not have a post-baseline tumor measurement were considered non-responders in the assessment of ORR.

    Time frame: Approximately 43 Months

Secondary outcomes

  1. Time to Disease Progression

    Time to disease progression was assessed as the time from start of treatment to the time the participant was first recorded as having disease progression or died due to causes other than disease progression. If a participant never progressed while being followed, he/she was censored at the date of the last tumor assessment or the date of the last dose if no post-baseline tumor measurement was available.

    Time frame: Approximately 43 Months

  2. Time to Treatment Failure

    Time to treatment failure was assessed as the time from start of treatment to the time the participant was withdrawn due to any of the reasons such as adverse events, progressive disease, insufficient therapeutic response, death, failure to return, or refused treatment, did not cooperate or withdrew consent.

    Time frame: Approximately 43 Months

  3. Percentage of Participants With One-year Survival

    Survival was measured as the time from start of treatment to the date of death or till one year whichever occurred first.

    Time frame: Up to Month 12

  4. Overall Survival

    Overall Survival is defined as the time from start of treatment to the date of death. Participants who did not die were censored at the last date the participant was known to be alive.

    Time frame: Approximately 43 Months

  5. Time To Objective Response

    The time to objective response is defined as the time from start of treatment to the date of first objective response. Participants who never responded during study were censored at the last tumor assessment or the date of last dose, whichever was later, or at the date of death if occurring prior to response.

    Time frame: Approximately 43 Months

  6. Duration of Overall Response

    Duration of overall response was assessed from the time that measurement criteria were first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease was documented. It was analyzed for responders only. Participants without observed progressive disease after an objective response were censored at the date of the last tumor assessment.

    Time frame: Approximately 43 Months

  7. Duration of Overall Complete Response

    The duration of overall complete response was assessed from the time that measurement criteria were met for complete response until the first date that recurrent or progressive disease was objectively documented. Participants without observed progressive disease after an objective complete response were censored at the date of the last tumor assessment.

    Time frame: Approximately 43 Months

  8. Number of Participants With Any Adverse Events, Serious Adverse Events and Deaths

    An adverse event (AEs) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), life-threatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above.

    Time frame: Approximately 43 Months

07

Results

Posted Apr 15, 2016

Participant flow

A total of 67 participants were enrolled in the study, which was conducted from 18 May 2001 to 9 December 2004 at 18 study centers in the United States.

Participant flow — Overall Study
MilestoneCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
Started1552
Completed717
Not completed835
Withdrew: Adverse event59
Withdrew: Death02
Withdrew: Failure to return01
Withdrew: Refused treatment02
Withdrew: Insufficient therapeutic response214
Withdrew: Administrative /other17

Outcome measures

PrimaryTumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0)

Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as a greater than or equal to (\>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD. Participants who did not have a post-baseline tumor measurement were considered non-responders in the assessment of ORR.

Time frame:
Approximately 43 Months
Reported as:
Number · percentage of participants
Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0)
percentage of participantsCohort 1, Initial Regimen:(Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
CR72
PR4042
SecondaryTime to Disease Progression

Time to disease progression was assessed as the time from start of treatment to the time the participant was first recorded as having disease progression or died due to causes other than disease progression. If a participant never progressed while being followed, he/she was censored at the date of the last tumor assessment or the date of the last dose if no post-baseline tumor measurement was available.

Time frame:
Approximately 43 Months
Reported as:
Median · months
Time to Disease Progression
monthsCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
Time to Disease Progression6.1 (3.4 to 9.0)7.6 (5.8 to 8.7)
SecondaryTime to Treatment Failure

Time to treatment failure was assessed as the time from start of treatment to the time the participant was withdrawn due to any of the reasons such as adverse events, progressive disease, insufficient therapeutic response, death, failure to return, or refused treatment, did not cooperate or withdrew consent.

Time frame:
Approximately 43 Months
Reported as:
Median · months
Time to Treatment Failure
monthsCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
Time to Treatment Failure5.8 (2.4 to 9.2)7.3 (4.6 to 9.5)
SecondaryPercentage of Participants With One-year Survival

Survival was measured as the time from start of treatment to the date of death or till one year whichever occurred first.

Time frame:
Up to Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With One-year Survival
percentage of participantsCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
Percentage of Participants With One-year Survival67 (43 to 91)71 (58 to 83)
SecondaryOverall Survival

Overall Survival is defined as the time from start of treatment to the date of death. Participants who did not die were censored at the last date the participant was known to be alive.

Time frame:
Approximately 43 Months
Reported as:
Median · months
Overall Survival
monthsCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
Overall Survival22.9 (10.1 to 28.2)20.5 (14.9 to 30.0)
SecondaryTime To Objective Response

The time to objective response is defined as the time from start of treatment to the date of first objective response. Participants who never responded during study were censored at the last tumor assessment or the date of last dose, whichever was later, or at the date of death if occurring prior to response.

Time frame:
Approximately 43 Months
Reported as:
Median · months
Time To Objective Response
monthsCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
Time To Objective Response5.5 (2.7 to 8.6)4.3 (2.6 to 9.6)
SecondaryDuration of Overall Response

Duration of overall response was assessed from the time that measurement criteria were first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease was documented. It was analyzed for responders only. Participants without observed progressive disease after an objective response were censored at the date of the last tumor assessment.

Time frame:
Approximately 43 Months
Reported as:
Median · months
Duration of Overall Response
monthsCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
Duration of Overall Response7.0 (2.6 to 9.2)7.7 (5.8 to 11.5)
SecondaryDuration of Overall Complete Response

The duration of overall complete response was assessed from the time that measurement criteria were met for complete response until the first date that recurrent or progressive disease was objectively documented. Participants without observed progressive disease after an objective complete response were censored at the date of the last tumor assessment.

Time frame:
Approximately 43 Months
Reported as:
Number · months
Duration of Overall Complete Response
monthsCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
Duration of Overall Complete Response12.4512.68
SecondaryNumber of Participants With Any Adverse Events, Serious Adverse Events and Deaths

An adverse event (AEs) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), life-threatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above.

Time frame:
Approximately 43 Months
Reported as:
Number · Number of participants
Number of Participants With Any Adverse Events, Serious Adverse Events and Deaths
Number of participantsCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)Total Participants (Cohort 1 + Cohort 2)
Any AEs155267
SAEs102535
Deaths During Study033
Deaths During Follow-up132336

Adverse events

Collected over Approximately 43 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)—10/15 (66.7%)15/15 (100%)
Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)—25/52 (48.1%)52/52 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
DehydrationMetabolism and nutrition disorders3/154/52
DiarrhoeaGastrointestinal disorders2/155/52
Deep vein thrombosisVascular disorders2/153/52
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/152/52
Small intestinal obstructionGastrointestinal disorders0/156/52
ColitisGastrointestinal disorders1/150/52
HyperglycaemiaMetabolism and nutrition disorders1/150/52
PneumoniaInfections and infestations1/150/52
SepsisInfections and infestations1/150/52
Febrile neutropeniaBlood and lymphatic system disorders1/151/52
Most frequent other events
Showing 10 of 109
Most frequent other events
EventCohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)
DiarrhoeaGastrointestinal disorders13/1545/52
NauseaGastrointestinal disorders13/1534/52
FatigueGeneral disorders8/1532/52
VomitingGastrointestinal disorders7/1526/52
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders7/1524/52
Abdominal painGastrointestinal disorders6/1524/52
AnaemiaBlood and lymphatic system disorders6/1518/52
AlopeciaSkin and subcutaneous tissue disorders3/1518/52
ConstipationGastrointestinal disorders5/1517/52
NeutropeniaBlood and lymphatic system disorders5/1516/52

Baseline characteristics

The All Patients Population included participants who received at least one dose of study drug in Cohort 1 or Cohort 2.

Age, Continuous
Age, Continuous(years)Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)Total
Mean63.1 ± 8.361.4 ± 11.161.8 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)Total
Female92130
Male63137
08

Study locations

17 sites
  • University of Alabama at Birmingham Comprehensive Cancer Center
    Birmingham, Alabama 35294-3300, United States
  • Loma Linda University Cancer Institute at Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • Eastern Connecticut Hematology and Oncology Associates
    Norwich, Connecticut 06360, United States
  • Lombardi Cancer Center at Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • George Washington University Medical Center
    Washington, District of Columbia 20037, United States
  • University of Florida Health Science Center - Jacksonville
    Jacksonville, Florida 32209, United States
  • Markey Cancer Center at University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536-0084, United States
  • St. Louis University Hospital Cancer Center
    Saint Louis, Missouri 63110-0250, United States
  • Lincoln Medical and Mental Health Center
    Bronx, New York 10451, United States
  • HemOnCare, P.C.
    Brooklyn, New York 11235, United States
  • Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
    Philadelphia, Pennsylvania 19107-5541, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Charleston Hematology-Oncology, P.A.
    Charleston, South Carolina 29403, United States
  • Cancer Center at the University of Virginia
    Charlottesville, Virginia 22908, United States
  • Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
    Seattle, Washington 98104, United States
  • Rockwood Clinic P.S.
    Spokane, Washington 99202, United States
  • West Virginia University Hospitals
    Morgantown, West Virginia 26506-9300, United States
09

References and documents

Publications

  • Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006 Sep 1;24(25):4069-77. doi: 10.1200/JCO.2005.05.2084. PubMed 16943524 ↗
  • Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36. PubMed 15709193 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2001, a primary completion of Dec 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 11 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2001
First posted
Jan 27, 2003
Start
May 2001
Primary completionActual
Dec 2004
CompletionActual
Dec 2004
Results first posted
Apr 15, 2016
Last update
Apr 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00022698
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 27, 2003
Start date
May 2001
Primary completion
Dec 2004
Completion
Dec 2004
Results posted
Apr 15, 2016
Last update
Apr 15, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Irinotecan

Start the discussion